This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Repros Provides Clinical Update For Androxal(R) Phase 3 Program

Stocks in this article: RPRX

  • First subjects enrolled in pivotal Phase 3 study
  • 158 men currently enrolled in 500 patient 6 month open label study
  • Repros believes open label study provides encouraging data to support pivotal study endpoint
  • Repros believes recent financing provides sufficient funds to submit Androxal NDA in 2014

THE WOODLANDS, Texas, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX)today provided a clinical update of its Androxal ® Phase 3 program.

Pivotal Phase 3 Studies

Repros has randomized the first subjects in ZA-301, the first of two pivotal studies. The study is being conducted at various US clinical sites.

The second Phase 3 study, ZA-302, will begin enrollment at many of the same sites after the completion of enrollment in the ZA-301 study. The FDA has agreed that Repros may conduct both identical Phase 3 studies at the same clinical sites as long as the two studies have a distinct principal investigator.

The Company has commenced an advertising campaign this week with the goal of increasing the enrollment rate into the Androxal Phase 3 program. The Company plans to provide an update in the fourth quarter of 2012, to project an estimated last patient last visit date for the first pivotal study and the estimated reporting date of top line results. Currently, the Company believes results from the first study could be available as early as the second quarter of 2013.

About the Pivotal Studies

The two identical pivotal studies are being conducted under a Special Protocol Assessment (SPA) granted by the FDA. The key features of the studies are:

  • Primary efficacy endpoint; success is defined as at least 75% of Androxal-treated men must achieve 24 hour average testosterone >300 ng/dL at week 12 -- All men in active arm start dosing at 12.5 mg with up-titration to 25 mg at week 6 if morning T remains less than 300 ng/dL -- Primary efficacy to be determined on Intent-to-Treat Population
  • Primary safety endpoint; comparison of active and placebo arm with respect to the percent of men that exhibit a 50% reduction in sperm counts between two assessments at baseline and two assessments at the end of the active dosing period. The active arm should be non-inferior to placebo.
  • 152 men randomized 3:1 active to placebo
  • BMI>25 and ≤ 60 years of age
  • 12 week active dosing period
  • Confirmed baseline morning testosterone levels <300 ng/dL determined on two separate days
  • Men must be naïve to testosterone treatment or off testosterone therapy for at least 6 months
  • Confirmed baseline sperm concentrations >15,000,000 sperm/mL determined on two separate days separated by at least 2 days

Six Month Open Label Study (ZA-300)

The Company is conducting a 500 subject open label study to build the size of the safety database to the exposure requirements the FDA has requested for the New Drug Application (NDA). The Company believes it will satisfy the 800 subjects with at least 6 months exposure requirement with ZA-300 and other studies it has already completed or will complete in order to satisfy the requirements for an NDA.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs